{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T22:06:35Z","timestamp":1784066795708,"version":"3.55.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.heliyon.2024.e35331","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T22:38:58Z","timestamp":1722033538000},"page":"e35331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Convenient screening of the reproductive toxicity of favipiravir and antiviral drugs in Caenorhabditis elegans"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5218-4249","authenticated-orcid":false,"given":"Kimiyasu","family":"Shiraki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Mishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Imoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoji","family":"Nishiwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e35331_bib1","series-title":"Fujifim ToyamaChemical Co. Ltd.","article-title":"AVIGAN Tablets 200mg package insert","author":"Fujifim","year":"2019"},{"key":"10.1016\/j.heliyon.2024.e35331_bib3","series-title":"Fact Sheet For Healthcare Providers: Emergency Use Authorization For Lagevrio\u2122 (molnupiravir) Capsules","year":"2023"},{"key":"10.1016\/j.heliyon.2024.e35331_bib4","year":"2020","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.heliyon.2024.e35331_bib5","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1126\/science.282.5396.2012","article-title":"Sequencing Consortium, Genome sequence of the nematode C. elegans: a platform for investigating biology","volume":"282","author":"elegans","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.heliyon.2024.e35331_bib6","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nature03001","article-title":"Human Genome Sequencing, Finishing the euchromatic sequence of the human genome","volume":"431","author":"International","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e35331_bib7","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/hmg\/9.6.869","article-title":"A role for Caenorhabditis elegans in understanding the function and interactions of human disease genes","volume":"9","author":"Culetto","year":"2000","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.heliyon.2024.e35331_bib8","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1002\/tox.22373","article-title":"Reproductive toxicity induced by nickel nanoparticles in Caenorhabditis elegans","volume":"32","author":"Kong","year":"2017","journal-title":"Environ. Toxicol."},{"key":"10.1016\/j.heliyon.2024.e35331_bib9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/toxsci\/kfn121","article-title":"Caenorhabditis elegans: an emerging model in biomedical and environmental toxicology","volume":"106","author":"Leung","year":"2008","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.heliyon.2024.e35331_bib10","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/jat.3357","article-title":"The C. elegans model in toxicity testing","volume":"37","author":"Hunt","year":"2017","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.heliyon.2024.e35331_bib11","first-page":"1","article-title":"Caenorhabditis elegans, a biological model for research in toxicology","volume":"237","author":"Tejeda-Benitez","year":"2016","journal-title":"Rev. Environ. Contam. Toxicol."},{"key":"10.1016\/j.heliyon.2024.e35331_bib12","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1152\/physiolgenomics.00063.2018","article-title":"Comparative genomic analysis of the human and nematode Caenorhabditis elegans uncovers potential reproductive genes and disease associations in humans","volume":"50","author":"Kim","year":"2018","journal-title":"Physiol. Genom."},{"key":"10.1016\/j.heliyon.2024.e35331_bib31","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nature08283","article-title":"An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA","volume":"461","author":"Maida","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e35331_bib32","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.1111\/cas.14618","article-title":"RNA-dependent RNA polymerase, RdRP, a promising therapeutic target for cancer and potentially COVID-19","volume":"111","author":"Machitani","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.heliyon.2024.e35331_bib40","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1128\/MCB.01021-15","article-title":"De novo RNA synthesis by RNA-dependent RNA polymerase activity of telomerase reverse transcriptase","volume":"36","author":"Maida","year":"2016","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.heliyon.2024.e35331_bib13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/genetics\/77.1.71","article-title":"The genetics of Caenorhabditis elegans","volume":"77","author":"Brenner","year":"1974","journal-title":"Genetics"},{"key":"10.1016\/j.heliyon.2024.e35331_bib14","series-title":"PMDA Report on the Deliberation Results","article-title":"CTD for avigan tablets 200 mg","year":"2014"},{"key":"10.1016\/j.heliyon.2024.e35331_bib15","author":"GlaxoSmithKline"},{"key":"10.1016\/j.heliyon.2024.e35331_bib16","series-title":"Report on the Deliberation Results (Avigan Tablet 200 Mg) in, Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau","year":"2014"},{"key":"10.1016\/j.heliyon.2024.e35331_bib17","author":"Genentech"},{"key":"10.1016\/j.heliyon.2024.e35331_bib19","series-title":"Amenalief Tablets (200mg)","author":"Maruho Co","year":"2023"},{"key":"10.1016\/j.heliyon.2024.e35331_bib20","series-title":"Amenalief Tablets (200mg) CTD","author":"Maruho Co","year":"2020"},{"key":"10.1016\/j.heliyon.2024.e35331_bib22","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/jac\/5.4.431","article-title":"The activity in vitro against herpes virus of 9-(2-hydroxyethoxymethyl)guanine (acycloguanosine), a new antiviral agent","volume":"5","author":"Collins","year":"1979","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.heliyon.2024.e35331_bib23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.antiviral.2016.04.003","article-title":"Susceptibilities of enterovirus D68, enterovirus 71, and rhinovirus 87 strains to various antiviral compounds","volume":"131","author":"Smee","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.heliyon.2024.e35331_bib24","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1254\/jphs.FP0071679","article-title":"Phenoxazine derivatives inactivate human cytomegalovirus, herpes simplex virus-1, and herpes simplex virus-2 in vitro","volume":"106","author":"Hayashi","year":"2008","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.heliyon.2024.e35331_bib25","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1167\/iovs.10-5671","article-title":"In vitro synergism of trifluorothymidine and ganciclovir against HSV-1","volume":"52","author":"Hobden","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.heliyon.2024.e35331_bib26","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1128\/AAC.46.4.977-981.2002","article-title":"In vitro and in vivo activities of anti-influenza virus compound T-705","volume":"46","author":"Furuta","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.heliyon.2024.e35331_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/v14020234","article-title":"The synthesis and anti-cytomegalovirus activity of piperidine-4-carboxamides","volume":"14","author":"Guo","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.heliyon.2024.e35331_bib28","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/jac\/dkq198","article-title":"ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2","volume":"65","author":"Chono","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.heliyon.2024.e35331_bib29","doi-asserted-by":"crossref","first-page":"8333","DOI":"10.1073\/pnas.83.21.8333","article-title":"Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase","volume":"83","author":"Furman","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.heliyon.2024.e35331_bib30","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0012-1606(76)90119-6","article-title":"The life cycle of the nematode Caenorhabditis elegans. I. Wild-type growth and reproduction","volume":"51","author":"Byerly","year":"1976","journal-title":"Dev. Biol."},{"key":"10.1016\/j.heliyon.2024.e35331_bib90","series-title":"WormAtlas","year":"2002"},{"key":"10.1016\/j.heliyon.2024.e35331_bib91","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ydbio.2021.01.006","article-title":"Human gastrulation: the embryo and its models","volume":"474","author":"Ghimire","year":"2021","journal-title":"Dev. Biol."},{"key":"10.1016\/j.heliyon.2024.e35331_bib92","series-title":"Gastrulation in C. elegans","first-page":"1","author":"Nance","year":"2005"},{"key":"10.1016\/j.heliyon.2024.e35331_bib93","first-page":"146","article-title":"The maternal-to-zygotic transition revisited","author":"Vastenhouw","year":"2019","journal-title":"Development"},{"key":"10.1016\/j.heliyon.2024.e35331_bib33","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/0014-4827(61)90192-6","article-title":"The serial cultivation of human diploid cell strains","volume":"25","author":"Hayflick","year":"1961","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.heliyon.2024.e35331_bib34","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0022-5193(73)90198-7","article-title":"A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon","volume":"41","author":"Olovnikov","year":"1973","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.heliyon.2024.e35331_bib35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/molehr\/gat055","article-title":"Telomere length and telomerase activity during oocyte maturation and early embryo development in mammalian species","volume":"20","author":"Ozturk","year":"2014","journal-title":"Mol. Hum. Reprod."},{"key":"10.1016\/j.heliyon.2024.e35331_bib36","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/molehr\/gaq048","article-title":"Telomere lengths in human oocytes, cleavage stage embryos and blastocysts","volume":"16","author":"Turner","year":"2010","journal-title":"Mol. Hum. Reprod."},{"key":"10.1016\/j.heliyon.2024.e35331_bib37","first-page":"8","article-title":"The expression of miRNAs in human ovaries, oocytes, extracellular vesicles, and early embryos: a systematic review","author":"Salas-Huetos","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.heliyon.2024.e35331_bib38","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/35053110","article-title":"Role for a bidentate ribonuclease in the initiation step of RNA interference","volume":"409","author":"Bernstein","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e35331_bib39","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.heliyon.2024.e35331_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/v13081547","article-title":"Amenamevir, a helicase-primase inhibitor, for the optimal treatment of herpes zoster","volume":"13","author":"Shiraki","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.heliyon.2024.e35331_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104829","article-title":"Viral ribonucleotide reductase attenuates the anti-herpes activity of acyclovir in contrast to amenamevir","volume":"180","author":"Shiraki","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.heliyon.2024.e35331_bib43","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1358\/dot.2017.53.11.2724803","article-title":"Helicase-primase inhibitor amenamevir for herpesvirus infection: towards practical application for treating herpes zoster","volume":"53","author":"Shiraki","year":"2017","journal-title":"Drugs Today"},{"key":"10.1016\/j.heliyon.2024.e35331_bib45","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1006\/faat.1996.0117","article-title":"Nonclinical toxicology studies with zidovudine: reproductive toxicity studies in rats and rabbits","volume":"32","author":"Greene","year":"1996","journal-title":"Fund. Appl. Toxicol."},{"key":"10.1016\/j.heliyon.2024.e35331_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110114","article-title":"Recent advances in the molecular mechanism of thalidomide teratogenicity","volume":"127","author":"Gao","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.heliyon.2024.e35331_bib47","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis","volume":"91","author":"D'Amato","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.heliyon.2024.e35331_bib48","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.heliyon.2024.e35331_bib49","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1038\/s41589-019-0366-7","article-title":"p63 is a cereblon substrate involved in thalidomide teratogenicity","volume":"15","author":"Asatsuma-Okumura","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.heliyon.2024.e35331_bib50","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020105375","article-title":"Thalidomide and its metabolite 5-hydroxythalidomide induce teratogenicity via the cereblon neosubstrate PLZF","volume":"40","author":"Yamanaka","year":"2021","journal-title":"EMBO J."},{"key":"10.1016\/j.heliyon.2024.e35331_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/bdrb.10054","article-title":"Effects of thalidomide on reproductive function and early embryonic development in male and female New Zealand white rabbits","volume":"71","author":"Teo","year":"2004","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"10.1016\/j.heliyon.2024.e35331_bib52","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/jama.1963.63700020034021b","article-title":"Congenital malformation in strain A mice. Its experimental production by thalidomide","volume":"183","author":"Dipaolo","year":"1963","journal-title":"JAMA"},{"key":"10.1016\/j.heliyon.2024.e35331_bib53","series-title":"Fujimoto Pharmaceutical Corp, Thaled\u00ae Capsule 25\/50\/100","year":"2021"},{"key":"10.1016\/j.heliyon.2024.e35331_bib54","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1124\/mol.64.2.415","article-title":"Thalidomide down-regulates transcript levels of GC-rich promoter genes in multiple myeloma","volume":"64","author":"Drucker","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e35331_bib55","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/BF00316250","article-title":"Gross-structural defects in rats after acyclovir application on day 10 of gestation","volume":"62","author":"Chahoud","year":"1988","journal-title":"Arch. Toxicol."},{"issue":"Suppl 1","key":"10.1016\/j.heliyon.2024.e35331_bib56","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0890-6238(93)90079-M","article-title":"Significance of embryo culture methods for studying the prenatal toxicity of virustatic agents","volume":"7","author":"Stahlmann","year":"1993","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.heliyon.2024.e35331_bib57","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/BF00293693","article-title":"Prenatal toxicity of acyclovir in rats","volume":"61","author":"Stahlmann","year":"1988","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.heliyon.2024.e35331_bib58","first-page":"190","article-title":"Monitoring pregnancy outcomes following prenatal drug exposure through prospective pregnancy registries and passive surveillance: a pharmaceutical company commitment","volume":"5","author":"Eldridge","year":"1998","journal-title":"Prim. Care Update OB\/GYNS"},{"key":"10.1016\/j.heliyon.2024.e35331_bib59","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1001\/jama.2010.1206","article-title":"Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects","volume":"304","author":"Pasternak","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.heliyon.2024.e35331_bib60","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/BF01968962","article-title":"In vitro and in vivo studies on the prenatal toxicity of five virustatic nucleoside analogues in comparison to aciclovir","volume":"65","author":"Klug","year":"1991","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.heliyon.2024.e35331_bib61","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1097\/00007890-199903150-00021","article-title":"Absence of teratogenicity of oral ganciclovir used during early pregnancy in a liver transplant recipient","volume":"67","author":"Pescovitz","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.heliyon.2024.e35331_bib62","first-page":"205","article-title":"In vitro and in vivo effect of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin) on types 1 and 3 parainfulenza virus infections","volume":"21","author":"Sidwell","year":"1975","journal-title":"Chemotherapy"},{"key":"10.1016\/j.heliyon.2024.e35331_bib63","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/00006454-200205000-00037","article-title":"Safety issues related to the administration of ribavirin","volume":"21","author":"Krilov","year":"2002","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.heliyon.2024.e35331_bib64","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/hep.23504","article-title":"Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials","volume":"51","author":"Awad","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.heliyon.2024.e35331_bib65","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1126\/science.401547","article-title":"Congenital anomalies induced in hamster embryos with ribavirin","volume":"195","author":"Kilham","year":"1977","journal-title":"Science"},{"key":"10.1016\/j.heliyon.2024.e35331_bib66","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jhep.2009.12.039","article-title":"Seminal fluid ribavirin level and functional semen parameters in patients with chronic hepatitis C on antiviral combination therapy","volume":"52","author":"Hofer","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e35331_bib67","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S1383-5718(01)00308-4","article-title":"Ribavirin-induced sperm shape abnormalities in Wistar rat","volume":"513","author":"Narayana","year":"2002","journal-title":"Mutat. Res."},{"key":"10.1016\/j.heliyon.2024.e35331_bib68","doi-asserted-by":"crossref","first-page":"933 e917","DOI":"10.1016\/j.fertnstert.2008.07.1755","article-title":"Ribavirin and pegylated interferon treatment for hepatitis C was associated not only with semen alterations but also with sperm deoxyribonucleic acid fragmentation in humans","volume":"91","author":"Pecou","year":"2009","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.heliyon.2024.e35331_bib69","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1097\/00006454-199009001-00008","article-title":"Effects of exposure to high concentrations of ribavirin in developing embryos","volume":"9","author":"Kochhar","year":"1990","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.heliyon.2024.e35331_bib70","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s40264-017-0566-6","article-title":"The ribavirin pregnancy registry: an interim analysis of potential teratogenicity at the mid-point of enrollment","volume":"40","author":"Sinclair","year":"2017","journal-title":"Drug Saf."},{"key":"10.1016\/j.heliyon.2024.e35331_bib71","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009103","article-title":"A multicenter non-randomized, uncontrolled single arm trial for evaluation of the efficacy and the safety of the treatment with favipiravir for patients with severe fever with thrombocytopenia syndrome","volume":"15","author":"Suemori","year":"2021","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.heliyon.2024.e35331_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103591","article-title":"Clinical efficacy and safety evaluation of favipiravir in treating patients with severe fever with thrombocytopenia syndrome","volume":"72","author":"Yuan","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.heliyon.2024.e35331_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108121","article-title":"Antiviral therapy for COVID-19: derivation of optimal strategy based on past antiviral and favipiravir experiences","volume":"235","author":"Shiraki","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.heliyon.2024.e35331_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107512","article-title":"Favipiravir, an anti-influenza drug against life-threatening RNA virus infections","volume":"209","author":"Shiraki","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.heliyon.2024.e35331_bib75","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.heliyon.2024.e35331_bib76","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/infdis\/jiv586","article-title":"Efficacy of favipiravir (T-705) in rabies postexposure prophylaxis","volume":"213","author":"Yamada","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e35331_bib77","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.antiviral.2018.03.003","article-title":"Favipiravir as a potential countermeasure against neglected and emerging RNA viruses","volume":"153","author":"Delang","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.heliyon.2024.e35331_bib78","article-title":"Experimental treatment with favipiravir for Ebola virus disease (the jiki trial): a historically controlled, single-arm proof-of-concept trial in Guinea","volume":"13","author":"Sissoko","year":"2016","journal-title":"PLoS Med."},{"key":"10.1016\/j.heliyon.2024.e35331_bib79","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S1473-3099(15)00228-5","article-title":"Post-exposure prophylaxis against Ebola virus disease with experimental antiviral agents: a case-series of health-care workers","volume":"15","author":"Jacobs","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e35331_bib80","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/cid\/ciaa1176","article-title":"AVIFAVIR for treatment of patients with moderate coronavirus disease 2019 (COVID-19): interim results of a phase II\/III multicenter randomized clinical trial","volume":"73","author":"Ivashchenko","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e35331_bib81","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.eng.2020.03.007","article-title":"Experimental treatment with favipiravir for COVID-19: an open-label control study","volume":"6","author":"Cai","year":"2020","journal-title":"Engineering"},{"key":"10.1016\/j.heliyon.2024.e35331_bib82","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/infdis\/jiz656","article-title":"Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection","volume":"221","author":"Wang","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e35331_bib83","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jiac.2022.10.008","article-title":"Favipiravir for symptomatic COVID-19: a nationwide observational cohort study","volume":"29","author":"Doi","year":"2023","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/j.heliyon.2024.e35331_bib84","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijid.2020.11.142","article-title":"Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial","volume":"103","author":"Udwadia","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e35331_bib85","doi-asserted-by":"crossref","DOI":"10.1007\/s40121-021-00517-4","article-title":"Efficacy and safety of favipiravir in moderate COVID-19 pneumonia patients without oxygen therapy: a randomized, phase III clinical trial","author":"Shinkai","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.heliyon.2024.e35331_bib86","article-title":"Favipiravir versus arbidol for COVID-19: a randomized clinical trial","author":"Chen","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.heliyon.2024.e35331_bib87","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejogrb.2021.12.001","article-title":"Favipiravir exposure and pregnancy outcome of COVID-19 patients","volume":"268","author":"Tirmikcioglu","year":"2022","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.heliyon.2024.e35331_bib88","first-page":"1","article-title":"The outcomes of favipiravir exposure in pregnancy: a case series","author":"Ertem","year":"2022","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.heliyon.2024.e35331_bib89","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/infdis\/jiab247","article-title":"beta-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells","volume":"224","author":"Zhou","year":"2021","journal-title":"J. Infect. Dis."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240584402411362X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240584402411362X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T22:01:02Z","timestamp":1784066462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240584402411362X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":89,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S240584402411362X"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e35331","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Convenient screening of the reproductive toxicity of favipiravir and antiviral drugs in Caenorhabditis elegans","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e35331","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e35331"}}